Skip to main content
Clinical Trials/NL-OMON40335
NL-OMON40335CompletedNot Applicable

Epigenetic biomarkers to predict psoriasis disease progression * towards tailored therapy. - Psoriasis Epigenetics

Maastricht Universitair Medisch Centrum +0 sites9 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
9

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • For psoriasis patients:
  • - Age: >18 years old
  • - No systemic therapy for psoriasis
  • - Clinical diagnosis: Psoriasis Vulgaris or Psoriasis Guttata (The diagnosis will be confirmed by a dermatologist)
  • - Topical therapy is OK if it IS possible to stop for 3 weeks;For the control group:
  • - Age: >18 years old
  • - No generalised skin disease

Exclusion Criteria

  • For psoriasis patients:
  • - Age: <18 years old
  • - Systemic therapy for psoriasis
  • - Juvenile psoriasis
  • - Not meeting the inclusion criteria
  • - Excessive scar formation or keloid in medical history
  • - Other (skin) disease that could influence the psoriasis
  • - Minors or incapacitated subjects
  • - Allergic reaction to lidocaine in medical history
  • - Topical therapy if it is NOT possible to stop for 3 weeks;For the control group:
  • - Clinical diagnosis of psoriasis
  • - Other generalised skin disease
  • - Excessive scar formation or keloid in medical history
  • - Minors or incapacitated subjects
  • - Allergic reaction to lidocaine in medical history

Investigators

Sponsor
Maastricht Universitair Medisch Centrum +

Similar Trials